We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
Radcal IBA  Group

Download Mobile App





Ground-Breaking One-Step COVID-19 Cartridge May Enable Large-Scale Antibody Testing

By HospiMedica International staff writers
Posted on 17 Aug 2020
A new one-step testing cartridge for COVID-19 antibody testing that will use a simplified procedure to eliminate operator error and deliver more consistent results will begin clinical studies by October.

The ground-breaking cartridge is being developed by Vivera Pharmaceuticals, Inc. More...
(Newport Beach, CA, USA), a pharmaceutical company focused on novel therapies for a variety of indications. To be tested, the user will simply obtain a drop of blood with a safety lancet and apply it directly on the cartridge. Upon closing the cartridge, the integrated blood flow system will automatically deliver the required amount of blood to the sample well, all while the internal buffer solution automatically releases, providing the exact volume of buffer needed for the test. Vivera is currently in discussions with top telemedicine providers in the US to develop effective testing protocols for the one-step cartridge once the FDA provides the appropriate pathways.

"The advantage of this new one-step testing cartridge is the simplification of the entire testing process," said Dr. Mehdi Hatamian, Vivera Pharmaceuticals Chief Scientific Advisor. "This technology will eventually allow for large-scale COVID-19 antibody testing and pave the way for future testing devices designed to greatly reduce the risk of human error."

"A consistent, user friendly, testing device will prove to be a vital tool for use not only at the point-of-care by medical professionals, but will open the door to the convenience of at-home testing for all," said Dr. Stephen McColgan Vivera Pharmaceuticals Chief Medical Officer. "As the world waits for a COVID-19 vaccine, we know that screening with antibody tests is the best way to help make more informed public health decisions."

"The availability of novel medical device technologies is exciting for the future expansion of our medical device division," said Paul Edalat Vivera Pharmaceuticals Chief Executive Officer. "A combination of innovative product development and strategic partnerships is really going to set Vivera apart in the coming months."

Related Links:

Vivera Pharmaceuticals, Inc.


Platinum Member
Real-Time Diagnostics Onscreen Viewer
GEMweb Live
Gold Member
SARS‑CoV‑2/Flu A/Flu B/RSV Sample-To-Answer Test
SARS‑CoV‑2/Flu A/Flu B/RSV Cartridge (CE-IVD)
Cardiograph Device
PageWriter TC35
Portable Jaundice Management Device
Nymphaea
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to HospiMedica.com and get access to news and events that shape the world of Hospital Medicine.
  • Free digital version edition of HospiMedica International sent by email on regular basis
  • Free print version of HospiMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of HospiMedica International in digital format
  • Free HospiMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Surgical Techniques

view channel
Image: Professor Bumsoo Han and postdoctoral researcher Sae Rome Choi of Illinois co-authored a study on using DNA origami to enhance imaging of dense pancreatic tissue (Photo courtesy of Fred Zwicky/University of Illinois Urbana-Champaign)

DNA Origami Improves Imaging of Dense Pancreatic Tissue for Cancer Detection and Treatment

One of the challenges of fighting pancreatic cancer is finding ways to penetrate the organ’s dense tissue to define the margins between malignant and normal tissue. Now, a new study uses DNA origami structures... Read more

Patient Care

view channel
Image: The portable biosensor platform uses printed electrochemical sensors for the rapid, selective detection of Staphylococcus aureus (Photo courtesy of AIMPLAS)

Portable Biosensor Platform to Reduce Hospital-Acquired Infections

Approximately 4 million patients in the European Union acquire healthcare-associated infections (HAIs) or nosocomial infections each year, with around 37,000 deaths directly resulting from these infections,... Read more
Copyright © 2000-2026 Globetech Media. All rights reserved.